Last updated: August 26, 2026
Teveten HCT, a fixed-dose combination of eprosartan mesylate and hydrochlorothiazide, is a mature antihypertensive product with limited current commercial relevance. Its market position weakened after loss of exclusivity, generic substitution, broad competition from lower-cost ARB/thiazide combinations, and the withdrawal or discontinuation of branded distribution in major markets. Public filings do not provide standalone Teveten HCT revenue, so its financial trajectory must be assessed through product lifecycle, regulatory status, class-level competition, and manufacturer portfolio disclosures.
What is Teveten HCT and who marketed it?
Teveten HCT combines:
| Attribute |
Detail |
| Active ingredients |
Eprosartan mesylate and hydrochlorothiazide |
| Drug class |
Angiotensin II receptor blocker plus thiazide diuretic |
| Primary indication |
Hypertension |
| Dosage form |
Oral tablet |
| Brand |
Teveten HCT |
| Originator companies |
Solvay Pharmaceuticals and later Abbott Laboratories in the United States |
| Typical strengths |
Eprosartan/hydrochlorothiazide fixed-dose combinations, including 600/12.5 mg and 600/25 mg configurations |
| Regulatory pathway |
New drug application for a fixed-dose combination |
| Commercial status |
Mature, low-demand product with discontinued or limited branded availability in key markets |
Eprosartan blocks the angiotensin II type 1 receptor. Hydrochlorothiazide increases sodium and water excretion. The combination was intended for patients whose blood pressure was not adequately controlled by eprosartan alone or who required dual-mechanism treatment.
Teveten HCT competed against Cozaar HCT, Diovan HCT, Avalide, Benicar HCT, Hyzaar generics, valsartan/hydrochlorothiazide products, and numerous low-cost losartan, irbesartan, and candesartan combinations.
When did Teveten HCT lose exclusivity?
Teveten HCT lost its commercial exclusivity after the expiration of the core intellectual-property term covering eprosartan and the fixed-dose combination. The product is now well beyond the period in which branded patent protection could support premium pricing.
The relevant exclusivity trajectory was:
| Period |
Market event |
Commercial effect |
| Late 1990s to early 2000s |
Eprosartan and Teveten franchise launched and expanded |
Premium branded pricing and physician promotion |
| Early to mid-2000s |
Teveten HCT established as a combination option |
Revenue supported by cardiovascular sales infrastructure |
| Around the end of the core patent period |
Core compound and product protection expired |
Generic entry risk increased |
| Late 2000s to 2010s |
ARB class became heavily commoditized |
Price compression and declining promotional return |
| 2010s onward |
Branded availability declined in the United States and other markets |
Product became a low-priority or discontinued asset |
The precise commercial loss-of-exclusivity date depends on the jurisdiction and on whether a patent term adjustment, pediatric extension, regulatory exclusivity period, or local supplementary protection certificate applied. The U.S. FDA’s Orange Book and Drugs@FDA records are the controlling sources for U.S. patent and regulatory status.[1,2]
What is the FDA regulatory status of Teveten HCT?
Teveten HCT is an FDA-approved antihypertensive combination associated with the eprosartan product family. The FDA has historically listed Teveten and Teveten HCT in Drugs@FDA materials, while later records indicate discontinued marketing status rather than a safety-driven withdrawal.[1]
The distinction matters:
- A discontinued product is not necessarily withdrawn because of safety or efficacy concerns.
- A product may remain in FDA databases after commercial distribution stops.
- Discontinuation can reflect low demand, portfolio rationalization, manufacturing economics, or inability to compete with generic combinations.
- FDA discontinuation status does not imply that no foreign-market version remains available.
The U.S. commercial outcome appears to have been driven primarily by market economics. ARB/thiazide combinations became interchangeable in prescribing and reimbursement, while eprosartan lacked the scale of losartan, valsartan, and irbesartan.
What is the Orange Book status of Teveten HCT?
The Orange Book is the principal U.S. source for approved products, therapeutic-equivalence codes, and listed patents or exclusivity. For a mature product such as Teveten HCT, the key commercial conclusion is that no current, enforceable U.S. patent estate appears to support meaningful branded exclusivity.
The practical Orange Book implications are:
| Issue |
Teveten HCT implication |
| Listed product |
Historical FDA-approved product record |
| Current branded protection |
No meaningful remaining market exclusivity |
| Patent barrier |
Core protection is expired or commercially exhausted |
| Generic substitution |
Permitted where an FDA-approved therapeutically equivalent product is available |
| Paragraph IV exposure |
Primarily historical rather than a current strategic risk |
| Commercial defense |
Limited to manufacturing, supply, trademark, or market-access advantages |
No active market strategy should rely on Teveten HCT patent protection in the United States. Any acquisition or licensing valuation would need to exclude conventional branded-LOE economics unless a buyer identified a new formulation, delivery platform, or geographic opportunity.
What patents protect Teveten HCT?
The historical patent estate centered on eprosartan, its pharmaceutical salts, intermediates, formulations, and combinations with hydrochlorothiazide. The original estate was developed during the period when ARB products were being commercialized as differentiated branded therapies.
Core composition and compound patents
Eprosartan protection was based primarily on compound and pharmaceutical-composition claims. Those patents covered the active molecule and related medicinal use. Their terms were tied to filing dates in the early development period and have expired in the United States.
Fixed-dose combination patents
Combination protection could cover:
- Eprosartan combined with hydrochlorothiazide.
- Specific dosage ratios.
- Tablet compositions.
- Manufacturing processes.
- Treatment of hypertension using the combination.
These claims typically provide a narrower barrier than a fundamental compound patent. Once generic manufacturers can market separate components or design around a narrow formulation claim, the commercial value of combination protection falls.
Formulation and manufacturing protection
Potential formulation claims included tablet composition, excipient selection, dissolution characteristics, stability, and production methods. Such patents rarely sustain significant revenue after the core molecule becomes generic unless they control a clinically meaningful delivery advantage.
The commercial barriers for Teveten HCT are therefore weak. The historical patents may remain relevant to litigation research and freedom-to-operate analysis, but they do not create a current premium-price position.
How many patents cover Teveten HCT?
The answer depends on whether the analysis counts only U.S. Orange Book patents, the broader eprosartan family, foreign counterparts, expired patents, formulation patents, and manufacturing applications. For current commercial purposes, the number of unexpired U.S. patents that could block generic Teveten HCT is effectively zero based on the product’s mature lifecycle and discontinued commercial status.
A historical patent review would normally separate:
- Eprosartan compound patents.
- Eprosartan salt and crystal-form patents.
- Eprosartan manufacturing patents.
- Eprosartan/hydrochlorothiazide combination patents.
- Dosage-form and stability patents.
- Method-of-use patents.
- Foreign national-stage counterparts.
The absence of a current blocking patent does not eliminate regulatory or supply-chain complexity. A manufacturer would still need an approved application, validated analytical methods, compliant active pharmaceutical ingredient supply, and evidence of bioequivalence where required.
Were there Paragraph IV challenges to Teveten HCT?
Paragraph IV litigation appears to have had limited lasting commercial impact on Teveten HCT. The product’s principal risk was the ordinary expiration of compound and formulation protection rather than a prolonged, high-value patent dispute comparable to major cardiovascular blockbusters.
For generic applicants, possible certification pathways would have included:
- Paragraph II certification where the relevant patent had expired.
- Paragraph III certification with a proposed launch after patent expiration.
- Paragraph IV certification alleging invalidity, unenforceability, or non-infringement.
- Section viii statements for patents that did not cover the proposed label.
The absence of a durable branded defense is consistent with the product’s later market status. No major, continuing Teveten HCT litigation appears to support a material current litigation premium.
What formulation and method-of-use patents protected Teveten HCT?
Formulation and method-of-use rights were secondary to the eprosartan compound estate.
Formulation patents
The most commercially relevant formulation claims would have involved fixed-dose tablets containing eprosartan and hydrochlorothiazide. These could address:
- Dose ratios.
- Tablet uniformity.
- Dissolution performance.
- Stability under storage.
- Manufacturing process controls.
- Excipients and coating systems.
Such patents can delay generic entry if they are listed and enforceable. Their value declines sharply when the product has limited volume and alternative ARB/thiazide combinations dominate formularies.
Method-of-use patents
Method-of-use claims could cover treatment of hypertension with eprosartan alone or in combination with a diuretic. These rights may be narrower than composition claims and can be vulnerable to label carve-outs, especially when the generic applicant omits a patented indication from its labeling.
For Teveten HCT, method-of-use protection did not create a durable commercial moat. Hypertension is a broad indication with many therapeutically substitutable products.
Which companies challenged or competed with Teveten HCT?
Teveten HCT competed with both branded cardiovascular companies and generic manufacturers.
| Competitor |
Product or class |
Competitive impact |
| Merck and legacy partners |
Cozaar and Cozaar HCT |
Stronger ARB brand recognition and broad prescriber use |
| Novartis |
Diovan and Diovan HCT |
Large global cardiovascular franchise |
| Bristol-Myers Squibb and Sanofi |
Avalide |
Direct ARB/thiazide combination competition |
| Daiichi Sankyo |
Benicar HCT |
Strong U.S. commercial presence |
| Generic manufacturers |
Losartan/HCTZ, valsartan/HCTZ, irbesartan/HCTZ |
Major price and formulary pressure |
| Regional manufacturers |
Eprosartan and combination products |
Local substitution in selected countries |
The competitive disadvantage was not only price. Eprosartan had lower prescribing scale and less entrenched guideline visibility than losartan, valsartan, and irbesartan. Physicians and payers generally had multiple ARB/thiazide options with similar treatment objectives.
How did Teveten HCT revenue change over time?
Standalone Teveten HCT revenue was not separately reported in the public filings of the originator companies. Solvay and Abbott reported cardiovascular or pharmaceutical segment results, but those disclosures did not provide a reliable product-level revenue series for Teveten HCT.[3,4]
The financial trajectory can therefore be summarized as follows:
Launch and franchise-building phase
Teveten HCT generated revenue as part of the broader Teveten franchise. Sales benefited from:
- Branded pricing.
- Combination-product convenience.
- Physician promotion.
- Cardiovascular portfolio distribution.
- Limited early generic substitution.
Mature branded phase
Revenue growth was constrained by:
- Competition from larger ARB franchises.
- Increasing payer pressure.
- Availability of alternative fixed-dose combinations.
- Limited differentiation in hypertension treatment.
- Dependence on a narrow active ingredient franchise.
Post-LOE phase
After patent protection weakened, expected revenue drivers changed from volume expansion to residual demand. Net sales would have been exposed to:
- Generic price erosion.
- Reduced detailing.
- Formulary exclusion.
- Wholesaler inventory rationalization.
- Lower patient retention after substitution.
- Discontinuation of branded supply.
The product’s economic value likely shifted from a revenue-generating brand to a portfolio-maintenance asset before disappearing from major commercial channels.
What is the current market size for Teveten HCT?
The current addressable market for the Teveten HCT brand is small. The relevant market is no longer the branded Teveten HCT market; it is the broader market for ARB/thiazide combinations and low-cost hypertension therapy.
Commercial demand is constrained by:
- Generic substitution.
- Availability of separate eprosartan and hydrochlorothiazide tablets in some jurisdictions.
- Use of more familiar ARBs.
- Fixed-dose combinations from multiple suppliers.
- Clinical preference for established first-line agents.
- Low willingness among payers to reimburse an older branded combination.
A relaunch would require either a major price discount, a new formulation, or a targeted geographic strategy. A conventional branded relaunch in the United States would face weak economics.
What generic entry risks exist for Teveten HCT?
Generic entry risk is high because the product is mature and its principal patent barriers have expired or lost practical force.
A generic manufacturer would face the following requirements:
- Confirmation of the applicable FDA application pathway.
- Demonstration of pharmaceutical equivalence.
- Bioequivalence testing.
- Validation of eprosartan and hydrochlorothiazide assay methods.
- Stability data for the fixed-dose tablet.
- Commercial-scale manufacturing capability.
- Compliance with current good manufacturing practice.
- Reliable API sourcing.
The key commercial risk is not legal entry. It is whether enough demand remains to support production, registration, and distribution costs. A generic Teveten HCT product could be technically approvable but commercially unattractive if prescription volume is low.
How does Teveten HCT compare with other ARB/thiazide combinations?
| Product class |
Relative market position |
Generic pressure |
Commercial outlook |
| Losartan/HCTZ |
Broad use and high generic availability |
Very high |
Large, low-margin market |
| Valsartan/HCTZ |
Historically strong global franchise |
High |
Established generic market |
| Irbesartan/HCTZ |
Strong hypertension positioning |
High |
Stable generic demand |
| Olmesartan/HCTZ |
Later-generation branded and generic option |
High |
More differentiated brand history |
| Eprosartan/HCTZ |
Narrower adoption |
High |
Limited residual opportunity |
| Candesartan/HCTZ |
Smaller but clinically established segment |
High |
Niche generic and branded demand |
Teveten HCT’s main disadvantage is lower franchise scale. The combination did not establish the same level of prescriber familiarity or payer preference as the largest ARB products.
What is the biosimilar risk for Teveten HCT?
Biosimilar risk is not applicable. Teveten HCT is a small-molecule drug, not a biologic. Its competitive threat comes from conventional generic drugs, authorized generics, therapeutic substitution, and alternative ARB combinations.
The regulatory and commercial analysis should therefore focus on:
- Abbreviated new drug applications.
- Bioequivalence.
- Orange Book patents.
- Therapeutic-equivalence ratings.
- Generic price competition.
- Pharmacy substitution.
Biosimilar development timelines and biologic interchangeability rules do not apply.
What licensing deals affected Teveten HCT?
Teveten HCT was associated with the broader Solvay cardiovascular franchise, which later became part of Abbott’s pharmaceutical portfolio through Abbott’s acquisition of Solvay’s pharmaceutical business. That transaction transferred commercial and intellectual-property interests in Solvay’s pharmaceutical products, including the Teveten franchise, subject to jurisdiction-specific portfolio arrangements.[5]
The transaction had strategic importance for asset ownership but did not reverse Teveten HCT’s lifecycle pressures. Abbott’s portfolio included larger growth products and therapeutic areas with stronger commercial prospects. A mature ARB combination had limited ability to attract incremental promotional investment.
No major recent licensing transaction appears to assign a material standalone value to Teveten HCT.
What patent litigation and settlement agreements affect Teveten HCT?
There is no current high-value litigation structure comparable to major pharmaceutical patent disputes involving blockbuster cardiovascular products. Any historical litigation would be relevant mainly to the timing of generic entry and the validity of formulation or combination claims.
Commercial diligence should treat Teveten HCT litigation exposure as low relative to:
- Product discontinuation risk.
- Regulatory reactivation costs.
- Supply-chain risk.
- Low prescription volume.
- Generic price competition.
Settlement agreements, if any, would be historical and would need to be reviewed against the relevant jurisdiction, patent family, and generic applicant. They should not be assumed to create current launch restrictions.
How strong is the Teveten HCT patent estate?
The current patent estate is weak from a commercial protection standpoint.
| Factor |
Assessment |
| Core compound protection |
Expired |
| Fixed-dose combination protection |
Expired or commercially ineffective |
| Method-of-use protection |
Narrow and unlikely to support premium pricing |
| Formulation protection |
Limited current value |
| Orange Book leverage |
Low |
| Generic litigation leverage |
Low |
| Manufacturing know-how |
Potentially relevant but unlikely to block entry |
| Trademark value |
Limited outside residual brand recognition |
| Geographic variation |
Material; some foreign rights or registrations may differ |
The product may still have technical know-how value, particularly in API sourcing, formulation scale-up, and stability control. That value is separate from patent exclusivity and would be difficult to monetize without meaningful demand.
What generic launch scenarios exist for Teveten HCT?
Three scenarios are commercially plausible:
No new U.S. generic launch
This is the most likely outcome if the remaining prescription base is too small to justify development and regulatory costs. Generic companies typically prioritize higher-volume fixed-dose combinations.
Limited regional generic launch
A manufacturer could supply eprosartan/hydrochlorothiazide in selected European, Latin American, Middle Eastern, or Asian markets where eprosartan remains registered and physician demand persists.
Low-price niche relaunch
A specialty or regional company could acquire rights, register the product, and market it as a low-cost alternative. This strategy would require minimal promotional spending and dependable API supply. It would generate modest revenue and would not restore the original branded economics.
What manufacturing and IP barriers remain?
The principal barriers are operational rather than patent-based:
- Limited or fragmented demand.
- API availability for eprosartan.
- Supplier qualification.
- Stability and dissolution performance.
- Regulatory maintenance costs.
- Manufacturing line economics.
- Distribution access.
- Reimbursement positioning.
- Product registration in each target country.
Eprosartan is less commercially ubiquitous than losartan or valsartan. That can increase sourcing costs and create minimum-order constraints. Hydrochlorothiazide is widely available and does not materially constrain manufacturing.
Key Takeaways
- Teveten HCT is an older fixed-dose combination of eprosartan and hydrochlorothiazide.
- Its U.S. commercial position is weak, with discontinued or limited branded availability.
- Core patent protection has expired, and no meaningful current U.S. exclusivity appears to support premium pricing.
- Generic-entry risk is high, but actual generic launch depends on residual demand and manufacturing economics.
- Standalone revenue was not disclosed by Solvay or Abbott, preventing a reliable product-level sales series.
- The main competitors are generic losartan/HCTZ, valsartan/HCTZ, irbesartan/HCTZ, olmesartan/HCTZ, and candesartan/HCTZ.
- Biosimilar risk does not apply because Teveten HCT is a small-molecule product.
- The most realistic commercial opportunity is a low-cost regional generic or niche relaunch, not a U.S. branded revival.
- Current value lies primarily in residual registrations, supply capability, and selected geographic markets rather than patent exclusivity.
FAQs
Is Teveten HCT still available in the United States?
Teveten HCT has limited or discontinued U.S. commercial availability. FDA database status and current wholesaler supply should be distinguished because a product can remain listed in FDA records after marketing stops.[1]
What is the generic name for Teveten HCT?
The generic composition is eprosartan mesylate and hydrochlorothiazide. Availability of an approved or marketed equivalent varies by country.
Is eprosartan safer than losartan?
Available product labeling does not establish a broad safety advantage for eprosartan over losartan. Choice generally depends on clinical response, tolerability, patient factors, formulary coverage, and physician judgment.
Can a company relaunch Teveten HCT after discontinuation?
A company could pursue relaunch through the applicable regulatory pathway if the product application, manufacturing controls, labeling, and supply arrangements support commercial distribution. Relisting or reactivation would not restore expired patent exclusivity.
Does Teveten HCT have value in emerging markets?
Potential value may exist in countries where eprosartan remains registered, generic competition is less developed, and fixed-dose combination supply is limited. The opportunity would be regional and price-sensitive rather than a global branded franchise.
References
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- Abbott Laboratories. (2009). Annual report. Abbott Laboratories.
- Solvay S.A. (2008). Annual report. Solvay S.A.
- Abbott Laboratories. (2010). Annual report. Abbott Laboratories.
